Farida Sarsekbayeva
Research Subjects
Farida Sarsekbayeva has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Lyazzat Manzhuova
«Scientific Center of Pediatrics and Pediatric Surgery» JSC
2 shared publications - Abay Kussainov
Department of Neonatology, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan
1 shared publication - Aigul Bazarbayeva
Scientific Centre of Pediatric and Pediatric Surgery, Al-Farabi Avenue 146, Almaty 050060, Kazakhstan
1 shared publication - Aigul Kalieva
NJSC "Astana Medical University", Astana, Republic of Kazakhstan
1 shared publication - Aigulsum Kulyntayevna Izekenova
Department of Public Health, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan
1 shared publication - Akmaral Abikulova
Department of Health Policy and Management, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
1 shared publication
Latest Publications
- 28 April 2026
- Published by S. Karger AG in Ocular Oncology and Pathology
- p. 1-9
Retinoblastoma in Kazakhstan: Incidence Trends and Survival Analysis (2015–2024)
Introduction: Retinoblastoma (Rb) is a rare but aggressive pediatric eye cancer. This study aimed to examine its epidemiological characteristics, diagnostic stages, and survival factors in Kazakhstan, where national-level data have previously been limited. Methods: A retrospective national registry study was conducted using data from the Scientific Center for Pediatrics and Pediatric Surgery, the country’s referral center for Rb (2015–2024). Incidence was calculated using a birth cohort approach per 100,000 live births. Demographic and clinical characteristics, including diagnostic intervals (lag time 1: symptom onset to diagnosis; lag time 2: diagnosis to treatment initiation), were analyzed. Survival was estimated using Kaplan-Meier methods. Prognostic factors were assessed using univariate and multivariable Cox proportional hazards regression. Results: A total of 167 cases were recorded. The cumulative birth cohort incidence was 4.18 per 100,000 live births (1:23,915). Median age at diagnosis was 14 months (IQR: 6.5–27.5). Unilateral disease occurred in 78.4% of patients, and 76.9% were diagnosed at advanced stages (D or E). Extraocular involvement was observed in 9.8% of affected eyes. Hereditary Rb accounted for 6% of cases. Median lag time 1 was 60 days (IQR: 30–120), and median lag time 2 was 12 days (IQR: 7–20). Overall mortality was 11.4%, with most deaths occurring within 18 months. Older age at diagnosis (adjusted HR: 1.031; 95% CI: 1.008–1.054; p = 0.009) and longer lag time 2 (adjusted HR: 1.006; 95% CI: 1.004–1.008; p < 0.001) were independently associated with increased mortality. Conclusion: Rb in Kazakhstan remains characterized by a high proportion of advanced-stage disease and measurable early mortality. Delays in treatment initiation and older age at diagnosis independently predict poorer survival, underscoring the need to strengthen early detection and optimize care pathways.
- 28 April 2026
- Published by S. Karger AG in Ocular Oncology and Pathology
- p. 1-9
Retinoblastoma in Kazakhstan: Incidence Trends and Survival Analysis (2015–2024)
Introduction: Retinoblastoma (Rb) is a rare but aggressive pediatric eye cancer. This study aimed to examine its epidemiological characteristics, diagnostic stages, and survival factors in Kazakhstan, where national-level data have previously been limited. Methods: A retrospective national registry study was conducted using data from the Scientific Center for Pediatrics and Pediatric Surgery, the country’s referral center for Rb (2015–2024). Incidence was calculated using a birth cohort approach per 100,000 live births. Demographic and clinical characteristics, including diagnostic intervals (lag time 1: symptom onset to diagnosis; lag time 2: diagnosis to treatment initiation), were analyzed. Survival was estimated using Kaplan-Meier methods. Prognostic factors were assessed using univariate and multivariable Cox proportional hazards regression. Results: A total of 167 cases were recorded. The cumulative birth cohort incidence was 4.18 per 100,000 live births (1:23,915). Median age at diagnosis was 14 months (IQR: 6.5–27.5). Unilateral disease occurred in 78.4% of patients, and 76.9% were diagnosed at advanced stages (D or E). Extraocular involvement was observed in 9.8% of affected eyes. Hereditary Rb accounted for 6% of cases. Median lag time 1 was 60 days (IQR: 30–120), and median lag time 2 was 12 days (IQR: 7–20). Overall mortality was 11.4%, with most deaths occurring within 18 months. Older age at diagnosis (adjusted HR: 1.031; 95% CI: 1.008–1.054; p = 0.009) and longer lag time 2 (adjusted HR: 1.006; 95% CI: 1.004–1.008; p < 0.001) were independently associated with increased mortality. Conclusion: Rb in Kazakhstan remains characterized by a high proportion of advanced-stage disease and measurable early mortality. Delays in treatment initiation and older age at diagnosis independently predict poorer survival, underscoring the need to strengthen early detection and optimize care pathways.
- Open Access
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
Epidemiology of Childhood Cancer in the Republic of Kazakhstan: A Population-Based Registry Analysis (2015–2024). Saliyeva S.S1., Manzhuova L.N1., Bazarbayeva A.A1., Kussainov A.Z1., Sarsekbayeva F.M1, Kalieva A.Z2., Manapova M.M2., Kyzdarbekova Z.N2, Nurgaliev D.ZH3
BackgroundStudying the epidemiology of cancer in any country allows us to identify problems in the healthcare system as a whole and predict their future burden. However, no large-scale studies of the epidemiology of childhood cancer have been conducted in Kazakhstan to date. This study is the first to analyze cancer incidence rates among children in the Republic of Kazakhstan using data from the country's population-based registry of childhood cancers.MethodsData on cancer cases diagnosed between the ages of 0 and 18 between 2015 and 2024 were obtained from the population-based cancer registry. Cases were grouped according to the International Classification of Childhood Cancer, 3rd edition (ICCC-3), based on morphology and primary anatomical site. Age-standardized incidence rates (ASR) were calculated using the direct standardization method and expressed per million children.ResultsThe overall average annual incidence rate among children in 2015-2024 was 102.6 cases per million, ranging from 85 to 107 cases. This rate was higher among boys (115.2 per million) than among girls (85.7 per million). When broken down by age, the incidence rates were highest among children aged 0-4 years. Leukemia, CNS tumors, and lymphomas were the most common diseases.ConclusionIn Kazakhstan, the incidence of cancer in children is lower than in developed countries. This study highlights the need for further research and understanding of differences in cancer patterns and risk factors in the region.
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEpidemiology of Childhood Cancer in the Republic of Kazakhstan: A Population-Based Registry Analysis (2015–2024). Saliyeva S.S1., Manzhuova L.N1., Bazarbayeva A.A1., Kussainov A.Z1., Sarsekbayeva F.M1, Kalieva A.Z2., Manapova M.M2., Kyzdarbekova Z.N2, Nurgaliev D.ZH3
BackgroundStudying the epidemiology of cancer in any country allows us to identify problems in the healthcare system as a whole and predict their future burden. However, no large-scale studies of the epidemiology of childhood cancer have been conducted in Kazakhstan to date. This study is the first to analyze cancer incidence rates among children in the Republic of Kazakhstan using data from the country's population-based registry of childhood cancers.MethodsData on cancer cases diagnosed between the ages of 0 and 18 between 2015 and 2024 were obtained from the population-based cancer registry. Cases were grouped according to the International Classification of Childhood Cancer, 3rd edition (ICCC-3), based on morphology and primary anatomical site. Age-standardized incidence rates (ASR) were calculated using the direct standardization method and expressed per million children.ResultsThe overall average annual incidence rate among children in 2015-2024 was 102.6 cases per million, ranging from 85 to 107 cases. This rate was higher among boys (115.2 per million) than among girls (85.7 per million). When broken down by age, the incidence rates were highest among children aged 0-4 years. Leukemia, CNS tumors, and lymphomas were the most common diseases.ConclusionIn Kazakhstan, the incidence of cancer in children is lower than in developed countries. This study highlights the need for further research and understanding of differences in cancer patterns and risk factors in the region.